Trials / Completed
CompletedNCT00617695
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
A Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study With Single-blind, Placebo-challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- Impax Laboratories, LLC · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zolmitriptan | 5mg nasal spray |
| DRUG | Placebo |
Timeline
- Start date
- 2003-09-01
- Completion
- 2004-10-01
- First posted
- 2008-02-18
- Last updated
- 2024-10-02
Source: ClinicalTrials.gov record NCT00617695. Inclusion in this directory is not an endorsement.